非酒精性脂肪性肝病对肠道炎症及通透性的影响

摘要/Abstract

摘要： 目的通过高脂饮食建立非酒精性脂肪性肝病(NAFLD)大鼠模型,观察NAFLD大鼠是否也同时伴随存在肠道炎症,并探讨NAFLD对肠道通透性的影响。方法 24只雄性大鼠以1∶1比例随机接受标准饲料和高脂饲料喂食18周,分别建立对照组和NAFLD大鼠模型。通过大鼠肝脏病理切片HE染色和油红O染色验证模型的成立,根据大鼠结肠病理切片HE染色观察是否存在肠道炎症进行进一步分组分析。使用酶联免疫吸附测定血浆二胺氧化酶、D-乳酸水平和内毒素水平,检测肠道通透性改变情况。结果与对照组相比,12只NAFLD大鼠肝脏均呈大泡和小泡性脂肪变以及气球样变,其中发现有7只大鼠的肠道存在轻度炎症细胞浸润,组织学符合肠道炎症改变;NAFLD组中另5只大鼠未见组织学上肠道炎症改变;而在对照组中未见任何肠道炎症改变。与对照组相比,NAFLD大鼠血浆中二胺氧化酶和D-乳酸水平显著升高(P<0.05)。其中,NAFLD伴肠道炎症组大鼠的D-乳酸水平较NAFLD不伴肠道炎症组显著升高(P<0.05)。NAFLD伴肠道炎症组大鼠血浆中LBP水平明显高于对照组和NAFLD不伴肠道炎症组(均P<0.05)。结论 NAFLD可增加肠道炎症发生的风险,NAFLD导致肠道炎症时肠道通透性显著增加。

关键词: 非酒精性脂肪性肝病, 肠道, 炎症, 通透性

Abstract: Objective To investigate the effect of nonalcoholic fatty liver disease (NAFLD) on intestinal inflammation and permeability. Methods Twenty-four male rats were equally and randomly divided into control and NAFLD group, which were fed with standard diet and high fat diet for 18 weeks, respectively. The NAFLD rat model was validated by liver histological examination and further grouped by pathological examination of intestinal. Serum levels of diamine oxidase (DAO), D-lactate and endotoxin were detected to evaluate intestinal permeability by enzyme-linked immunosorbent assay. Results Histologically compared with control group, NAFLD group showed macro and micro vesicular fatty degeneration and ballooning, including 7 rats with mild inflammatory cell infiltration in the intestinal tract. By contract, no intestinal inflammation change was detected in control group. Compared with those in control group, serum levels of DAO and D-lactate increased significantly in NAFLD group (P<0.05). Among NAFLD group, the rats with intestinal inflammation showed higher level of D-lactate than that without intestinal inflammation (P<0.05). Furthermore, the plasma lipopolysaccharide-binding protein (LBP) level in NAFLD group with intestinal inflammation was significantly higher than that in control group or NAFLD group without intestinal inflammation (both P<0.05), respectively. Conclusion NAFLD might increase the risk of intestinal inflammation and enhance the intestinal permeability.

Key words: Nonalcoholic fatty liver disease, Intestine, Inflammation, Permeability

张静怡,李春敏,唐颖悦,明雅南,刘晓琳,曾民德,茅益民. 非酒精性脂肪性肝病对肠道炎症及通透性的影响[J]. 肝脏, 2017, 22(3): 219-223.

ZHANG Jing-yi,LI Chun-min,TANG Ying-yue,MING Ya-nan,LIU Xiao-lin,ZENG Min-de,MAO Yi-min. Effect of nonalcoholic fatty liver disease on intestinal inflammation and permeability[J]. Chinese Hepatolgy, 2017, 22(3): 219-223.

参考文献

[1] Tuyama AC, Chang CY. Non-alcoholic fatty liver disease. J Diabetes, 2012, 4: 266-280.
[2] Hjelkrem MC, Torres DM, Harrison SA. Nonalcoholic fatty liver disease. Minerva Med, 2008, 99: 583-593.
[3] Adams LA, Lymp JF, St SJ, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology, 2005, 129: 113-121.
[4] 陈一奕,范竹萍,茅益民,等. 非酒精性脂肪性肝病与代谢综合征的流行现状及相关性研究. 肝脏, 2008, 13: 456-458.
[5] Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol, 2015, 62(1 Suppl): S47-S64.
[6] Armstrong MJ, Adams LA, Canbay A, et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology, 2014, 59: 1174-1197.
[7] Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature reviews. Gastroenterol Hepatol, 2013, 10: 330.
[8] 茅益民,曾民德. 加强非酒精性脂肪性肝病的临床和转化医学研究. 实用肝脏病杂志, 2012, 15: 273-275.
[9] Lin X, Shi K, You J, et al. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. 2014, 41: 2989-2997.
[10] Huang KW, Leu HB, Wang YJ, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Disease, 2013, 15: 830-835.
[11] Min YW, Yun HS, Chang WI, et al. Influence of non-alcoholic fatty liver disease on the prognosis in patients with colorectal cancer. Clin Res Hepatol Gastroenterol, 2012, 36: 78-83.
[12] Muhidin SO, Magan AA, Osman KA, et al. The relationship between nonalcoholic fatty liver disease and colorectal cancer: The future challenges and outcomes of the metabolic syndrome. J Obes, 2012, 2012: 1-8.
[13] Lee YI, Lim Y, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: A retrospective cohort study. 2012, 27: 91-95.
[14] Wong VWS, Wong GLH, Tsang SWC, et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut, 2011, 60: 829-836.
[15] Tilg H, Diehl AM. NAFLD and extrahepatic cancers: have a look at the colon. Gut, 2011, 60: 745-746.
[16] Stadlmayr A, Aigner E, Steger B, et al. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. 2011, 270: 41-49.
[17] Hwang ST, Cho YK, Park JH, et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol, 2010, 25: 562-567.
[18] Wang QZ, Chen XP, Huang JP, et al. Effects of Couplet Medicines (Astragalus Membranaceus and Jiaozhen) on Intestinal Barrier in Postoperative Colorectal Cancer Patients. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2015, 35: 1307-1312.
[19] Sun Z, Wang X, Wallen R, et al. The influence of apoptosis on intestinal barrier integrity in rats. Scand J Gastroenterol, 1998, 33: 415-422.
[20] Yao YM, Yu Y, Wu Y, et al. Plasma D (-)-lactate as a new marker for diagnosis of acute intestinal injury following ischemia-reperfusion. World J Gastroenterol, 1997, 3: 225-227.
[21] Feng S, Liu W, Zuo S, et al. Impaired function of the intestinal barrier in a novel sub-health rat model. Mol Med Rep, 2016, 13: 3459-3465.
[22] Meng Y, Zhang Y, Liu M, et al. Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate. Anticancer Agents Med Chem, 2016, 16: 387-392.
[23] Xing X, Jiang R, Wang L, et al. Shenfu injection alleviates intestine epithelial damage in septic rats. Am J Emerg Med, 2015, 33: 1665-1670.
[24] Csak T, Ganz M, Pespisa J, et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology, 2011, 54: 133-144.